Yescarta
(Axicabtagene ciloleucel)Phase 3Cell therapy
GileadThis medication is used to treat a specific type of blood cancer called non-Hodgkin's lymphoma that has come back or stopped responding to other treatments. It works by using the patient's own immune cells, which are collected and specially modified to recognize and attack cancer cells.[1] Yescarta is currently being investigated across 9 indications[3], with its most advanced program in Phase 3.[1]
Yescarta is one of 182 cell therapy programs targeting Prevention. It is currently in Phase 3.
9
Indications
36
Total Trials
19
Active Trials
181
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Yescarta
GileadPhase 3
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Cabenuva
GSKPreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lymphoma16 trials
Show 13 more trials
Follicular Lymphoma3 trials
Diffuse Large B-Cell Lymphoma2 trials
Neurotoxicity1 trial
13 more indications
Treatment1 trial
Encephalopathy1 trial
Long-term Follow-up1 trial
T Cell Therapy1 trial
Mantle Cell Lymphoma1 trial
Large B-cell Lymphoma1 trial
AIDS-Related Diffuse Large B-cell Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Axicabtagene ciloleucel. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]